Beta Drugs Ltd

Beta Drugs Ltd Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Beta Drugs Ltd

₹ 1,730 -0.57%
15 Jul - close price
Company website NSE - SME: BETA
About

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Key Points

Market Position
The company is ranked among the top 10 oncology companies, and many of its key products are ranked among the top 5 in their respective categories. [1]

Website NSE - SM
  • Market Cap ₹ 1,746 Cr.
  • Current Price ₹ 1,730
  • High / Low ₹ 2,215 / 1,144
  • Stock P/E 38.1
  • Book Value ₹ 195
  • Dividend Yield 0.00 %
  • ROCE 27.3 %
  • ROE 25.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 37.1% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.6%

Cons

  • Stock is trading at 8.86 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Mar 2020 Sep 2020 Mar 2021 Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025
47 44 51 65 88 96 112 115 141 154 180 182
37 36 41 51 68 73 86 88 108 127 141 146
Operating Profit 9 8 11 14 20 23 27 26 33 27 39 36
OPM % 20% 19% 21% 22% 23% 24% 24% 23% 23% 18% 22% 20%
0 0 0 0 0 0 0 0 1 1 2 0
Interest 1 2 1 1 1 1 1 1 1 1 2 5
Depreciation 2 2 3 4 3 4 5 6 5 4 6 7
Profit before tax 7 5 7 9 16 18 21 20 27 22 33 24
Tax % 27% 14% 21% 30% 28% 27% 25% 25% 25% 25% 25% 26%
5 4 5 7 12 13 16 15 20 17 24 18
EPS in Rs 5.07 4.25 5.13 6.48 11.63 12.95 15.67 14.73 19.67 16.40 24.20 17.81
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
51 66 91 116 184 227 296 362
41 54 73 91 141 174 236 288
Operating Profit 9 12 18 25 43 53 60 75
OPM % 19% 18% 20% 21% 23% 23% 20% 21%
0 0 0 0 1 1 1 2
Interest 1 1 3 2 2 2 3 7
Depreciation 2 3 4 7 7 10 10 13
Profit before tax 7 8 12 16 34 41 49 57
Tax % 1% -2% 21% 27% 28% 25% 25% 26%
7 8 9 12 25 31 36 42
EPS in Rs 7.43 8.84 9.33 11.60 24.58 30.42 36.08 42.02
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 32%
3 Years: 25%
TTM: 23%
Compounded Profit Growth
10 Years: %
5 Years: 37%
3 Years: 23%
TTM: 26%
Stock Price CAGR
10 Years: %
5 Years: 98%
3 Years: 39%
1 Year: 44%
Return on Equity
10 Years: %
5 Years: 26%
3 Years: 27%
Last Year: 26%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 9 9 10 10 10 10 10 10
Reserves 24 32 48 59 83 113 148 187
8 20 23 17 21 20 15 133
9 22 28 31 45 55 82 106
Total Liabilities 50 83 107 118 158 198 254 436
13 18 44 40 55 63 65 89
CWIP 1 15 0 3 0 0 0 0
Investments 0 0 0 1 1 1 0 0
35 50 63 74 102 135 190 347
Total Assets 50 83 107 118 158 198 254 436

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
17 0 8 19 30 23 31 36
-11 -21 -15 -6 -22 -19 -14 -36
5 12 9 -8 -1 -2 -7 118
Net Cash Flow 12 -9 2 5 7 2 9 118

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 104 139 128 106 90 101 98 103
Inventory Days 37 104 102 100 87 106 122 127
Days Payable 81 143 119 127 123 139 145 152
Cash Conversion Cycle 60 100 111 79 53 68 75 79
Working Capital Days 75 100 95 88 70 88 86 88
ROCE % 18% 21% 22% 36% 34% 33% 27%

Shareholding Pattern

Numbers in percentages

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
66.71% 66.71% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73%
0.29% 0.29% 0.29% 0.29% 0.32% 0.32% 0.32% 0.90% 1.16% 1.15% 0.90% 0.90%
0.04% 0.04% 0.04% 0.04% 0.02% 0.02% 0.06% 0.12% 0.16% 0.17% 0.17% 0.26%
32.96% 32.96% 32.94% 32.93% 32.93% 32.92% 32.87% 32.25% 31.95% 31.95% 32.20% 32.11%
No. of Shareholders 1,4071,4441,4241,4511,7221,9282,1162,3232,5672,8823,0543,139

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls